Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.

  PMID 41842971 · PMC13132380 · The Journal of clinical investigation · 2026 · 8 claims · 8 setups

  Full-text index only

  PRC2i/EZH2i alone or combined with AR inhibitors induce diverse cell state programs (CSPs) that increase tumor cell invasion, metastasis, and drug resistance despite only modest suppression of tumor growth.

  lncap pca pdx clinical viability tumor ic50

• Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.

  PMID 41325133 · PMC13037771 · Cancer research communications · 2026 · 7 claims · 4 setups

  Full-text index only

  A palbociclib lead-in prior to retifanlimab produced a high rate of immune-related adverse events, leading to halted enrollment.

  tumor peripheral patients single-cell high-parameter clinical

• Targeting KIFC1 to disrupt centrosome clustering and trigger anaphase catastrophe in small-cell lung cancer.

  PMID 41948931 · PMC13134724 · JCI insight · 2026 · 8 claims · 8 setups

  Full-text index only

  KIFC1 is overexpressed in SCLC compared with normal tissues and other cancer types

  sclc h146 clinical cancer immunofluorescence viability flow

• Proneural-mesenchymal antagonism dominates the patterns of phenotypic heterogeneity in glioblastoma.

  PMID 38433919 · PMC10905000 · iScience · 2024 · 8 claims · 8 setups

  Has reproduction · 100

  The four proposed GBM molecular subtypes (Proneural, Neural, Classical, Mesenchymal / NPC-like, OPC-like, AC-like, MES-like) are not mutually exclusive or independent of one another

  scrna-seq tcga-gbm gse131928 tumor gene pairwise principal

• RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cells.

  PMID 41940329 · PMC13049659 · iScience · 2026 · 8 claims · 8 setups

  Full-text index only

  RUVBL1 and RUVBL2 target gene sets are significantly depleted in MYCN-driven NB mouse tumors treated with ATR inhibitors (elimusertib, ceralasertib)

  th-mycn neuroblastoma clb-bar clb-ga rna-seq gene western